Lincoln Capital Corp’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $478K | Buy |
+1,900
| New | +$409K | 0.16% | 70 |
|
|
2024
Q2 | – | Sell |
-1,585
| Closed | -$289K | – | 83 |
|
|
2024
Q1 | $289K | Buy |
1,585
+110
| +7% | +$19K | 0.13% | 58 |
|
|
2023
Q4 | $229K | Sell |
1,475
-15
| -1% | -$2.19K | 0.11% | 69 |
|
|
2023
Q3 | $222K | Sell |
1,490
-310
| -17% | -$45.5K | 0.12% | 67 |
|
|
2023
Q2 | $243K | Sell |
1,800
-137
| -7% | -$20.1K | 0.12% | 63 |
|
|
2023
Q1 | $309K | Sell |
1,937
-996
| -34% | -$152K | 0.18% | 49 |
|
|
2022
Q4 | $474K | Sell |
2,933
-600
| -17% | -$92K | 0.29% | 41 |
|
|
2022
Q3 | $474K | Sell |
3,533
-563
| -14% | -$80.8K | 0.32% | 41 |
|
|
2022
Q2 | $627K | Buy |
4,096
+740
| +22% | +$113K | 0.4% | 40 |
|
|
2022
Q1 | $544K | Buy |
3,356
+456
| +16% | +$66.2K | 0.28% | 44 |
|
|
2021
Q4 | $393K | Hold |
2,900
| – | – | 0.19% | 50 |
|
|
2021
Q3 | $313K | Hold |
2,900
| – | – | 0.17% | 48 |
|
|
2021
Q2 | $327K | Sell |
2,900
-436
| -13% | -$49.1K | 0.19% | 43 |
|
|
2021
Q1 | $361K | Hold |
3,336
| – | – | 0.23% | 42 |
|
|
2020
Q4 | $357K | Hold |
3,336
| – | – | 0.23% | 40 |
|
|
2020
Q3 | $292K | Hold |
3,336
| – | – | 0.21% | 42 |
|
|
2020
Q2 | $328K | Buy |
+3,336
| New | +$294K | 0.26% | 40 |
|
|
2020
Q1 | – | Sell |
-6,279
| Closed | -$556K | – | 45 |
|
|
2019
Q4 | $556K | Sell |
6,279
-895
| -12% | -$74.3K | 0.41% | 38 |
|
|
2019
Q3 | $543K | Sell |
7,174
-168
| -2% | -$11.5K | 0.46% | 37 |
|
|
2019
Q2 | $534K | Sell |
7,342
-703
| -9% | -$55.3K | 0.47% | 40 |
|
|
2019
Q1 | $648K | Sell |
8,045
-2,008
| -20% | -$164K | 0.59% | 35 |
|
|
2018
Q4 | $927K | Sell |
10,053
-463
| -4% | -$40.7K | 0.85% | 35 |
|
|
2018
Q3 | $995K | Sell |
10,516
-22,703
| -68% | -$2.15M | 0.83% | 31 |
|
|
2018
Q2 | $3.08M | Sell |
33,219
-1,490
| -4% | -$146K | 2.86% | 16 |
|
|
2018
Q1 | $3.29M | Sell |
34,709
-11,074
| -24% | -$1.22M | 3.05% | 14 |
|
|
2017
Q4 | $4.43M | Sell |
45,783
-3,578
| -7% | -$337K | 3.78% | 9 |
|
|
2017
Q3 | $4.39M | Sell |
49,361
-966
| -2% | -$73.5K | 3.92% | 9 |
|
|
2017
Q2 | $3.65M | Buy |
50,327
+475
| +1% | +$31.9K | 3.23% | 15 |
|
|
2017
Q1 | $3.25M | Sell |
49,852
-5,251
| -10% | -$330K | 2.9% | 13 |
|
|
2016
Q4 | $3.46M | Buy |
+55,103
| New | +$3.36M | 3.33% | 9 |
|
Other funds holding ABBV
Lincoln Capital Corp's ABBV Position: Q2 2026 in Review
Lincoln Capital Corp opened a new position in AbbVie (ABBV) in Q2 2026: 1,900 shares worth $478K. The stake represents 0.16% of the portfolio and ranks #70 among its holdings. This is a return to the name: Lincoln Capital Corp previously reported a position in ABBV as recently as Q1 2024.
Lincoln Capital Corp first reported a position in ABBV in Q4 2016 and has held it in 30 quarters since. The position peaked at $4.43M in Q4 2017. 4,215 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.
- Lincoln Capital Corp held 1,900 shares of AbbVie worth $478K as of Q2 2026.
- AbbVie was a new Lincoln Capital Corp position in Q2 2026.
- AbbVie made up 0.16% of Lincoln Capital Corp's portfolio in Q2 2026, its #70 holding.
- Lincoln Capital Corp first reported a position in AbbVie in Q4 2016 and has held it in 30 quarters since.
- Lincoln Capital Corp's AbbVie position peaked at $4.43M in Q4 2017.
- 4,215 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.
Based on Lincoln Capital Corp's 13F filing for Q2 2026, filed 16 Jul 2026.